ClinicalTrials.gg
RecruitingNCT06409351Updated Apr 27, 2026

Multi-modal Training Program to Promote Physical Activity After Stroke

An interventional study of Intervention group in Stroke and Physical Inactivity, sponsored by Singapore General Hospital. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Singapore General Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
21 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 104 studies in Stroke with a site in Singapore — 16 open to participants now, 21 under way, 1 of them phase 3. Stroke · Singapore.

Planned enrollment
32nd of 86
120 · median 51
Started
2024
with 11 others
No phase
58 of 104
13 open now
Primary completion
2026-12
later than 9 of 20 live
Registered
85th of 104
by date
Lead sponsor
7 of 104
Singapore General Hospital

Among the 104 studies in Stroke with a site in Singapore, this one is the 32nd largest by planned enrollment of the 86 interventional ones that give a count, is one of 12 that started in 2024, is one of 58 with no phase, reaches primary completion later than 9 of the 20 other live ones, and was the 85th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

16 of the 104 studies in Stroke with a site in Singapore are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 21 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Stroke with a site in Singapore, or all of them as a file.
02

Study summary

The goal of this study is to learn if a behavioral change intervention can improve physical activity in stroke survivors living in the community.

The main question it aims to answer is, if a behaviour change intervention and personalised physical activity prescription, are effective in improving the time spent in moderate to vigorous physical activity amongst chronic stroke survivors.

Researchers will compare the intervention group to a control group, to see if physical activity counselling and a personalized physical activity prescription is more effective in improving moderate to vigorous physical activity, than usual care alone. The study period for each participant is 6 months. Assessments are conducted at month 1 (baseline), 3 and 6.

The control group will receive only usual care, which consists of an information sheet on physical activity with the following content: (1) Why be active and (2) How to be active (with URL links to resources and videos). The usual care is delivered at 3-time points during month 1, 3 and 6.

The intervention group will receive usual care and a behavioral change intervention. The behavioral change intervention consists of up to 6 individual physical activity counselling sessions and a personalized physical activity prescription. The 6 sessions will take place only during months 1 to 3 and there will be no intervention during months 4 to 6. Of the 6 sessions, 3 are conducted face-to-face and another 3 sessions will take place using telehealth methods such as phone, text messaging and videoconference. Participants can meet the study physiotherapist at their preferred exercise space during the 3 face-to-face sessions. The physical activity counselling sessions consist of goal setting and action planning, and problem-solving barriers around participation in physical activity. The overall aim is to increase time spent in moderate-vigorous physical activity.

Read the detailed description

The MOTIVATE study will take place in Singapore with participants recruited through hospital-based stroke clinics, rehabilitation facilities, and stroke support organizations via posters, email, word of mouth, and social media. Potential participants can sign up by self-registering on the study URL link or through referrals from healthcare professionals and study members. Participants will be screened for eligibility via telephone using the inclusion and exclusion criteria and the Get Active Questionnaire. Participants. Those who have not engaged in regular exercise are required to obtain medical clearance. Informed consent will be taken by a study team member.

This trial will use a 1:1 concealed randomisation, to allocate participants with chronic stroke to an intervention group (n= 60) or control group (n = 60). Between-group comparisons will be made at 3 time points: months 1, 3 and 6.

The control group will receive usual care, which consists of 3 face-to-face sessions on general physical activity recommendations, lasting 30 to 60 minutes each during months 1, 3, and 6. Participants will be given an information sheet on the importance and benefits of physical activity after a stroke and general guidelines on how to start to be active. The general guidelines on how to be active include engaging in 150 minutes of moderate-intensity physical activity per week. The information sheet will also include links to publicly accessible online resources.

The intervention group will receive a behavioural change intervention, in addition to usual care. Information sheet about general guidelines on physical activity will be handed to the intervention group, as per control group. Each participant will receive up to 6 sessions of tailored behavioural change intervention during months 1 to 3 and there will be no intervention during months 4 to 6. Of the 6 sessions, 3 are face-to-face and another 3 will take place using telehealth methods such as phone, text messaging and videoconference. The tailoring of the intervention allows participants to decide the location during face-to-face sessions, how many sessions and how the sessions are spaced out during the 3-month intervention period and which sessions are face-to-face or telehealth. The preferred meeting location may include exercise spaces within home, common spaces just outside their homes and under their housing blocks, outdoor fitness zones or parks near home and residential or inclusive public gyms. The behavioural change intervention consists of physical activity counselling and prescription of a personalized physical activity plan. The first session will be conducted in-person, to allow the study physiotherapist to identify the participant's physical function, safety concerns and the impact of medical, social, environmental and resources on mobility. During the initial visit, the venue, frequency and mode of support (face-to-face or virtual) for subsequent sessions will be established. The study physiotherapist will provide physical activity counselling, set goals and discuss action plans to enhance moderate intensity physical activity, problem solve barriers on physical activity and prescribe a personalized physical activity plan. Subsequent sessions can include (1) training on physical activity modification to accommodate the weak arm and / leg at the participant's preferred exercise location, (2) taking videos of the personalized adapted exercises using the participant's phone when meeting face-to-face and (3) in-person or virtual support sessions to review physical activity progress and action plans.

A process and cost-utility evaluation will be embedded into the study design and conducted concurrently.

03

Conditions studied

  • Stroke
  • Physical Inactivity

Keywords

  • Physical activity
  • Behavioural change
  • Implementation Science
  • Stroke
04

Who can participate

Ages eligible
21 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 21 years and over
  • Haemorrhagic or ischaemic stroke
  • At least 6 months post-stroke
  • Living at home
  • Able to walk independently +/- gait aid short distances (self-reported)
  • Have sufficient cognition and/or carer support to engage in the interventions (clinical judgement)
  • Agreement to undertake a supported self-management physical activity intervention programme

Exclusion criteria

Exclusion Criteria:

  • Living in residential care
  • Unstable cardiac conditions, severe arthritis, or other conditions limiting the ability to exercise
  • Advised by GP/consultant not to undertake moderate-intensity exercise for health reason
  • Currently already participating in physical activity that meets recommended levels (150mins of moderate-vigorous physical activity)
  • Enrolled in another physical activity intervention trial
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Study period: 6 months (1st 3 months intervention, last 3 months no intervention) No. of sessions: up to 6 per participant Mode: 3 sessions are conducted face-to-face and 3 sessions via telehealth methods e.g. phone, text message or video conferencing using virtual platforms like zoom. Where: Face-to-face at the participant's preferred exercise space like home, outdoor fitness zone, parks, gyms etc. Duration of sessions: each face-to-face session will take 60-90 mins Details of intervention: Physical activity counselling on adaptation of exercises, goal setting, action planning, problem solving around barriers to physical activity and provision of study resources

    Behavioral: Intervention group

  • Active comparator
    Control group

    Study period: 6 months No. of sessions: 2 sessions (at month 1 and 3) Mode: Face-to-face Where: At the participant's home Duration of session: 20- 30 minutes Details of control: physical activity information without any other support.

    Behavioral: Intervention group

Interventions

  • BehavioralIntervention group

    Please refer to arm descriptions

    Also known as: MOTIVATE

06

What researchers measure

Primary outcomes

  1. Duration of moderate to vigorous physical activity

    Average minutes/day, measured by Fitbit Inspire 3 tracker

    Time frame: Initial assessment (month 1), month 3 and 6 follow-up.

Secondary outcomes

  1. Number of steps per day

    Number of steps per day, measured by Fitbit Inspire 3 tracker

    Time frame: Initial assessment (month 1), month 3 and 6 follow-up.

  2. International Physical Activity Questionnaire Short Form (IPAQ-SF)

    Duration (in minutes) and frequency (days) of walking, moderate-intensity, and vigorous-intensity activity, which are used to compute the total score.

    Time frame: Initial assessment (month 1), month 3 and 6 follow-up.

  3. Modified Rankin Scale

    0\. No symptoms 1. No significant disability despite symptoms; able to carry out all usual duties and activities 2. Slight disability: unable to carry out all previous activities but able to look after own affairs without assistance 3. Moderate disability: requiring some help, but able to walk without assistance 4. Moderately severe disability: unable to walk without assistance, and unable to attend to own bodily needs without assistance 5. Severe disability: bedridden, incontinent, and requiring constant nursing care and attention Outcome data: One score from a 6-point scale of 0-5.

    Time frame: Initial assessment (month 1), month 3 and 6 follow-up.

  4. Functional Ambulation Category

    0\) Patient cannot walk, or needs help from 2 or more persons 1. Patients needs firm continuous support from 1 person who helps carrying weight and with balance 2. Patient needs continuous or intermittent support of one person to help with balance and coordination 3. Patient requires verbal supervision or stand-by help from one person without physical contact 4. Patient can walk independently on level ground, but requires help on stairs, slopes or uneven surfaces 5. Patient can walk independently anywhere Outcome data: One score from a 6-point scale of 0-5

    Time frame: Initial assessment (month 1), month 3 and 6 follow-up.

  5. Comfortable gait speed

    Comfortable walking speed equals to predetermined distance divided by the average time taken from 2 trials to walk that distance comfortably or naturally (e.g., 5m/\_\_sec).

    Time frame: Initial assessment (month 1), month 3 and 6 follow-up.

  6. Fast gait speed

    Fast walking speed equals to predetermined distance divided by the average time taken from 2 trials to walk that distance as fast as possibly safe (e.g., 5m/\_\_sec).

    Time frame: Initial assessment (month 1), month 3 and 6 follow-up.

  7. Life-space Assessment Measure

    For the five "Life-Space Levels," each "Yes" is given a point value, starting with 1 (life-space level 1) and increasing by 1 point for each life-space level (2 for "Yes" in life-space level 2, 3 for "Yes" in life-space level 3, etc.). For frequency of each life-space level \[less than 1 time per week (score = 1), 1-3 times per week (score = 2), 4-6 times per week (score = 3), or daily (score = 4)\]. For independence level, requiring assistance or use of any equipment \[personal assistance (score = 1), equipment only (score = 1.5), or neither equipment nor personal assistance (score = 2)\]. Outcome data: The total score ranges from 0 ("totally bed-bound") to 120 ("traveling out of town every day without assistance").

    Time frame: Initial assessment (month 1), month 3 and 6 follow-up.

  8. Fall Efficacy Scale International (FES-I)

    The Short FES-I consists of seven items Each item is scored on a 4-point scale: 1. Not concerned at all 2. Somewhat concerned 3. Fairly concerned 4. Very concerned Outcome data: Total score ranging from 7 (no concern about falling) to 28 (severe concern about falling).

    Time frame: Initial assessment (month 1), month 3 and 6 follow-up.

  9. Self-Efficacy for Exercise Scale (SEES)

    Consists of 9 questions on the individual's confidence in their ability to engage in exercise. Each item is rated on a 11-point scale. Score of 0 indicates "not confident", and score of 10 indicates "very confident". Outcome data: Total score ranges from 0 ("not confident" in own ability to engage in exercise) to 90 ("very confident" in own ability to engage in exercise)

    Time frame: Initial assessment (month 1), month 3 and 6 follow-up.

  10. Fatigue Severity Scale - 7 item (FSS-7)

    The FSS-7 consists of seven items, and the responses are scored on a seven-point scale, where 1 indicates "strongly disagree" and 7 indicates "strongly agree." Outcome data: Total score ranges from 7 to 49, with higher scores indicating more severe fatigue and greater impact on activities.

    Time frame: Initial assessment (month 1), month 3 and 6 follow-up.

  11. Fatigue screening tool (SF-CAT)

    Yes/no screening questions to 16 questions that cover fatigue, mood, sleep quality, new / uncontrolled conditions, physical / nutrition status, role of medication consumption of alcohol, new / undiagnosed cognitive impairment, speech and language disorder.

    Time frame: Initial assessment (month 1), month 3 and 6 follow-up.

  12. Depression and Anxiety (PHQ-4)

    The responses are scored on a four-point scale, where 0 indicates "not at all" and 3 indicates "nearly every day." Outcome data: Total score ranges from 0 to 12, with higher scores indicating greater severity of depression and anxiety symptoms.

    Time frame: Initial assessment (month 1), month 3 and 6 follow-up.

  13. Global Sleep Assessment Questionnaire (GSAQ)

    Consists of 11 questions, rated on a 4-point scale ("never", "sometimes", "usually", "always"). Outcome data: More "always" responses indicate better sleep quality.

    Time frame: Initial assessment (month 1), month 3 and 6 follow-up.

  14. EQ-5D

    Outcome data: index values are used in the estimation of quality-adjusted life year (QALY) gains in economic analysis.

    Time frame: Initial assessment (month 1), month 3 and 6 follow-up.

  15. Global Rating of Change on Physical Activity and Fatigue

    Score rated on a 15-point scale, ranging from -7 (a very great deal worse) to +7 (a very great deal better). A score of 0 indicates unchanged. Outcome data: One score from the 15-point scale.

    Time frame: Month 3 and 6 follow-up.

  16. Adapted Client Service Receipt Inventory (CSRI)

    Cost estimate of resource utilization to generate an average cost per participant

    Time frame: Initial assessment (month 1), month 3 and 6 follow-up.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke. 2004 Mar;35(3):731-5. doi: 10.1161/01.STR.0000116183.50167.D9. Epub 2004 Feb 5. PubMed 14764929 ↗
  • Turan TN, Nizam A, Lynn MJ, Egan BM, Le NA, Lopes-Virella MF, Hermayer KL, Harrell J, Derdeyn CP, Fiorella D, Janis LS, Lane B, Montgomery J, Chimowitz MI. Relationship between risk factor control and vascular events in the SAMMPRIS trial. Neurology. 2017 Jan 24;88(4):379-385. doi: 10.1212/WNL.0000000000003534. Epub 2016 Dec 21. PubMed 28003500 ↗
  • Fini NA, Bernhardt J, Said CM, Billinger SA. How to Address Physical Activity Participation After Stroke in Research and Clinical Practice. Stroke. 2021 Jun;52(6):e274-e277. doi: 10.1161/STROKEAHA.121.034557. Epub 2021 May 6. No abstract available. PubMed 33951930 ↗
  • WHO Guidelines on Physical Activity and Sedentary Behaviour. Geneva: World Health Organization; 2020. Available from http://www.ncbi.nlm.nih.gov/books/NBK566045/ PubMed 33369898 ↗
  • Billinger SA, Arena R, Bernhardt J, Eng JJ, Franklin BA, Johnson CM, MacKay-Lyons M, Macko RF, Mead GE, Roth EJ, Shaughnessy M, Tang A; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Clinical Cardiology. Physical activity and exercise recommendations for stroke survivors: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 Aug;45(8):2532-53. doi: 10.1161/STR.0000000000000022. Epub 2014 May 20. PubMed 24846875 ↗
  • Thilarajah S, Bower KJ, Pua YH, Tan D, Williams G, Larik A, Bok CW, Koh G, Clark RA. Modifiable Factors Associated With Poststroke Physical Activity at Discharge From Rehabilitation: Prospective Cohort Study. Phys Ther. 2020 May 18;100(5):818-828. doi: 10.1093/ptj/pzaa022. PubMed 31995190 ↗
  • Fini NA, Holland AE, Keating J, Simek J, Bernhardt J. How Physically Active Are People Following Stroke? Systematic Review and Quantitative Synthesis. Phys Ther. 2017 Jul 1;97(7):707-717. doi: 10.1093/ptj/pzx038. PubMed 28444348 ↗
  • Thilarajah S, Mentiplay BF, Bower KJ, Tan D, Pua YH, Williams G, Koh G, Clark RA. Factors Associated With Post-Stroke Physical Activity: A Systematic Review and Meta-Analysis. Arch Phys Med Rehabil. 2018 Sep;99(9):1876-1889. doi: 10.1016/j.apmr.2017.09.117. Epub 2017 Oct 19. PubMed 29056502 ↗
  • Moncion K, Biasin L, Jagroop D, Bayley M, Danells C, Mansfield A, Salbach NM, Inness E, Tang A. Barriers and Facilitators to Aerobic Exercise Implementation in Stroke Rehabilitation: A Scoping Review. J Neurol Phys Ther. 2020 Jul;44(3):179-187. doi: 10.1097/NPT.0000000000000318. PubMed 32516297 ↗
  • Committee for Proprietary Medicinal Products. Points to consider on switching between superiority and non-inferiority. Br J Clin Pharmacol. 2001 Sep;52(3):223-8. doi: 10.1046/j.0306-5251.2001.01397-3.x. No abstract available. PubMed 11560553 ↗
  • Yarnell CJ, Abrams D, Baldwin MR, Brodie D, Fan E, Ferguson ND, Hua M, Madahar P, McAuley DF, Munshi L, Perkins GD, Rubenfeld G, Slutsky AS, Wunsch H, Fowler RA, Tomlinson G, Beitler JR, Goligher EC. Clinical trials in critical care: can a Bayesian approach enhance clinical and scientific decision making? Lancet Respir Med. 2021 Feb;9(2):207-216. doi: 10.1016/S2213-2600(20)30471-9. Epub 2020 Nov 20. PubMed 33227237 ↗
  • Chang BH, Pocock S. Analyzing data with clumping at zero. An example demonstration. J Clin Epidemiol. 2000 Oct;53(10):1036-43. doi: 10.1016/s0895-4356(00)00223-7. PubMed 11027937 ↗
  • Thorn JC, Coast J, Cohen D, Hollingworth W, Knapp M, Noble SM, Ridyard C, Wordsworth S, Hughes D. Resource-use measurement based on patient recall: issues and challenges for economic evaluation. Appl Health Econ Health Policy. 2013 Jun;11(3):155-61. doi: 10.1007/s40258-013-0022-4. PubMed 23529715 ↗
  • Hodgson TA. Costs of illness in cost-effectiveness analysis. A review of the methodology. Pharmacoeconomics. 1994 Dec;6(6):536-52. doi: 10.2165/00019053-199406060-00007. PubMed 10155283 ↗
  • Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998 Apr-Jun;18(2 Suppl):S68-80. doi: 10.1177/0272989X98018002S09. PubMed 9566468 ↗

Individual participant data

Plan to share: Yes — The study protocol with the statistical analysis plan will be published in a peer-reviewed journal.

Supporting information: Study protocol, Statistical analysis plan

Time frame: To be published ahead of the completion of the trial

Access criteria: The protocol will be available as per the publishing journal's options.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 30 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2024
First posted
May 10, 2024
StartActual
Jun 11, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06409351
Collaborators
Singapore Institute of Technology, National Neuroscience Institute
Responsible party
Sponsor
First posted
May 10, 2024
Start date
Jun 11, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Apr 27, 2026

Study contacts

Juliana Wang, MSc
Contact
juliana.wang.y.y@sgh.com.sg
+6597124823
Shamala Thilarajah, PhD
Contact
shamala.thilarajah@sgh.com.sg
+6591160364
Shamala Thilarajah, PhD
principal investigator · Singapore General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion